<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00896831</url>
  </required_header>
  <id_info>
    <org_study_id>08461</org_study_id>
    <nct_id>NCT00896831</nct_id>
  </id_info>
  <brief_title>Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy</brief_title>
  <acronym>PORTOALEGRE</acronym>
  <official_title>Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aimed to assess the effectiveness and safety of L-ornithine-L-aspartate in the
      management of hepatic encephalopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic encephalopathy continues to be a major clinical problem in cirrhosis. Patients with
      minimal hepatic encephalopathy are at risk for accidents, had a decline in work performance,
      or complain of cognitive symptoms, with poor health-related quality of life. This study will
      compare L-ornithine-L-aspartate with placebo for 60 days to assess the effectiveness, safety
      and health-related quality of life of this drug.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">September 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psychometric tests and critical flicker frequency</measure>
    <time_frame>day 0, 15, 30, 45 and 60</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ammonia concentration</measure>
    <time_frame>time 0 and 60 days after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>time 0 and 60 days after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety analysis</measure>
    <time_frame>time 0 and 60 days after</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>L-ornithine-L-aspartate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 g L-ornithine-L-aspartate (1 sachet) three times per day for 60 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 g (1 sachet) of placebo comparator three times per day for 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-ornithine-L-aspartate</intervention_name>
    <description>L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days</description>
    <arm_group_label>L-ornithine-L-aspartate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo: 5 g (1 sachet) three times per day for 60 days</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhosis and diagnosis of minimal hepatic encephalopathy using psychometric tests and
             critical flicker frequency

        Exclusion Criteria:

          -  Hepatic encephalopathy grade 1 to 4

          -  Use of drugs to treatment of hepatic encephalopathy (lactulose, neomycin)

          -  Psychoactive substance use within 72 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mário R Álvares-da-Silva, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clínicas de Porto Alegre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>June 5, 2009</last_update_submitted>
  <last_update_submitted_qc>June 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mário Reis Álvares-da-Silva</name_title>
    <organization>Hospital de Clínicas de Porto Alegre</organization>
  </responsible_party>
  <keyword>minimal hepatic encephalopathy</keyword>
  <keyword>L-ornithine-L-aspartate</keyword>
  <keyword>psychometric test</keyword>
  <keyword>critical flicker frequency</keyword>
  <keyword>quality of life</keyword>
  <keyword>Treatment</keyword>
  <keyword>Health-related quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methylaspartate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

